Currently, the prognosis of HCC is known to be related to the infiltration and activation of immune cells [55, 56], whose presence participates in an inflamed TME [57, 58], supporting the observation that NAPSB can stimulate the immune response in the TME and play an anti-tumor role in HCC, thereby prolonging survival. The gene discussed is NAPSB; the disease is neoplasm.